4
MARKET OVERVIEW
Presents a concise view of industry direction, strategic priorities, and key indicators influencing market momentum.
4.2.1.1
TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING PLATFORMS
4.2.1.2
RISING DEMAND FOR PRECISION MEDICINE AND PERSONALIZED HEALTHCARE
4.2.2.1
HIGH CAPITAL INVESTMENT AND OPERATIONAL COSTS
4.2.3.1
EXPANDING APPLICATIONS IN CLINICAL DIAGNOSTICS
4.2.4.1
DATA MANAGEMENT AND STORAGE COMPLEXITY
4.3
UNMET NEEDS & WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN FRANCE HEALTHCARE INDUSTRY
5.2.4
TRENDS IN FRANCE BIOTECH INDUSTRY
5.5.1
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025
5.5.2
AVERAGE SELLING PRICE, BY SERVICE,
5.5.3
AVERAGE SELLING PRICE TREND, BY COUNTRY, 2023–2025
5.6
TRADE ANALYSIS (2021–2025)
5.6.1
EXPORT SCENARIO (HS CODE 3822.00 & 9027.00)
5.6.2
IMPORT SCENARIO (HS CODE 3822.00 & 9027.00)
5.7
KEY CONFERENCES & EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9
INVESTMENT & FUNDING SCENARIO
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1.1
SEQUENCING BY SYNTHESIS
6.1.2
ION SEMICONDUCTOR SEQUENCING
6.1.3
NANOPORE SEQUENCING
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
AUTOMATED SAMPLE PREPARATION SYSTEM
6.2.2
BIOINFORMATICS & DATA ANALYSIS PLATFORMS
6.2.3
CRISPR-BASED TARGETED SEQUENCING
6.3
ADJACENT TECHNOLOGIES
6.3.1
SINGLE-CELL SEQUENCING TECHNOLOGY
6.3.2
MULTIOMICS INTEGRATION
6.3.3
SPATIAL GENOMICS & TRANSCRIPTOMICS
6.3.4
GENE EDITING TECHNOLOGIES
6.7
IMPACT OF AI/ GEN AI ON FRANCE NEXT-GENERATION SEQUENCING MARKET
6.7.1
TOP USE CASES & MARKET POTENTIAL
6.7.2
BEST PRACTICES IN AI-ENABLED NEXT-GENERATION SEQUENCING WORKFLOWS
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN FRANCE NEXT-GENERATION SEQUENCING MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED SEQUENCING SOLUTIONS
7
SUSTAINABILITY & REGULATORY LANDSCAPE
7.1
REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY INITIATIVES
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2
DECISION-MAKING PROCESS
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
FRANCE NEXT-GENERATION SEQUENCING MARKET, BY OFFERING (MARKET SIZE, 2024–2031, USD MILLION)
10
FRANCE NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY TYPE (MARKET SIZE, 2024–2031, USD MILLION)
10.1.1
LIBRARY PREP KITS & REAGENTS
10.1.2
SEQUENCING KITS & REAGENTS
10.2.1
SEQUENCING PLATFORMS
10.2.2
LIBRARY PREPARATION PLATFORMS
10.3
BIOINFORMATICS TOOLS
10.3.1
DATA ANALYSIS SOFTWARE & WORKBENCHES
10.3.2
DATA VISUALIZATION TOOLS
NOTE 1: OTHER CONSUMABLES INCLUDE FLOW CELLS & PLATES, ADAPTERS, AND INDEX.
NOTE 2: OTHER TOOLS INCLUDE DATA COLLECTION SOFTWARE, FRAGMENT ANALYSIS SOFTWARE, GENOME ANNOTATION TOOLS & CLOUD PLATFORM FOR STORAGE AND DATA ANALYSIS, AND WORKFLOW AUTOMATION TOOLS.
11
FRANCE NEXT-GENERATION SEQUENCING PLATFORMS MARKET, BY TECHNOLOGY (MARKET SIZE, 2024–2031, USD MILLION)
11.2
SEQUENCING BY SYNTHESIS
11.3
ION SEMICONDUCTOR SEQUENCING
11.4
SINGLE-MOLECULE REAL-TIME SEQUENCING
11.6
0THER SEQUENCING TECHNOLOGIES
NOTE 3: OTHER SEQUENCING TECHNOLOGIES INCLUDE CRISPR-BASED SEQUENCING, OPTICAL MAPPING, ISH SEQUENCING, DNA NANOBALL SEQUENCING, COMBINATORIAL PROBE ANCHOR SYNTHESIS (CPAS), AND TRUE SINGLE-MOLECULE SEQUENCING, AMONG OTHERS.
12
FRANCE NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY WORKFLOW (MARKET SIZE, 2024–2031, USD MILLION)
12.2
SAMPLE PREPARATION/PRE-SEQUENCING
13
FRANCE NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY END USER (MARKET SIZE, 2024–2031, USD MILLION)
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.3
CLINICAL & DIAGNOSTICS LABORATORIES
13.4
ACADEMIC & RESEARCH INSTITUTES
14
FRANCE NEXT-GENERATION SEQUENCING SERVICES MARKET, BY TYPE (MARKET SIZE, 2024–2031, USD MILLION)
14.2
PRESEQUENCING SERVICES
14.2.1
SAMPLE PREPARATION/ISOLATION
14.2.2
LIBRARY PREPARATION & TARGET ENRICHMENT
14.3.1
EXOME & TARGETED RESEQUENCING AND CUSTOM PANELS
14.3.3
DE NOVO SEQUENCING
14.3.5
WHOLE-GENOME SEQUENCING
14.3.7
OTHER SEQUENCING SERVICES
14.4
BIOINFORMATICS & DATA ANALYSIS SERVICES
14.4.1
DATA ANALYSIS SERVICES
14.4.2
DATA VISUALIZATION & INTERPRETATION
14.4.3
DATA STORAGE & MANAGEMENT SERVICES
14.5
SERVICES FOR NGS PLATFORMS
NOTE 4: OTHER SEQUENCING SERVICES INCLUDE AMPLICON SEQUENCING, DIGITAL KARYOTYPING, EPIGENOMIC SEQUENCING, MICROBIOME SEQUENCING, AND METAGENOMICS.
15
FRANCE NEXT-GENERATION SEQUENCING SERVICES MARKET, BY WORKFLOW (MARKET SIZE, 2024–2031, USD MILLION)
16
FRANCE NEXT-GENERATION SEQUENCING SERVICES MARKET, BY END USER (MARKET SIZE, 2024–2031, USD MILLION)
16.2
HOSPITALS & CLINICAL LABORATORIES
16.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
16.4
ACADEMIC & RESEARCH INSTITUTES
NOTE 5: OTHER END USERS INCLUDE GOVERNMENT & REGULATORY AGENCIES, ENVIRONMENTAL & INDUSTRIAL ORGANIZATIONS, AND CONSUMER GENOMICS COMPANIES.
17
FRANCE NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION (MARKET SIZE, 2024–2031, USD MILLION)
17.2
DIAGNOSTIC APPLICATIONS
17.2.1
CANCER DIAGNOSTICS
17.2.2
INFECTIOUS DISEASE DIAGNOSTICS
17.2.3
REPRODUCTIVE HEALTH DIAGNOSTICS
17.2.4
OTHER DIAGNOSTIC APPLICATIONS
17.3
DRUG DISCOVERY & DEVELOPMENT
17.3.2
OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS
17.4
AGRICULTURE & ANIMAL RESEARCH
NOTE 6: OTHER DIAGNOSTIC APPLICATIONS INCLUDE RARE GENETIC AND COMPLEX DISEASES SUCH AS IMMUNOLOGICAL, METABOLIC, NEUROLOGICAL, AND CARDIOVASCULAR DISEASES.
NOTE 7: OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS INCLUDE BIOMARKER DISCOVERY, DRUG TARGET IDENTIFICATION/DRUG EFFECT, POLYPHARMACOLOGY, AND VACCINE & BIOPHARMA DEVELOPMENT.
NOTE 8: OTHER APPLICATIONS INCLUDE SYNTHETIC BIOLOGY, MARINE RESEARCH, AND RESEARCH IN BIOFUELS, FORENSICS, METAGENOMICS & MICROBIOME ANALYSIS, AND EVOLUTIONARY STUDIES.
18.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
18.3
REVENUE ANALYSIS, 2021–2025
18.4
MARKET SHARE ANALYSIS,
18.5.2
THERMO FISHER SCIENTIFIC INC.
18.5.3
AGILENT TECHNOLOGIES, INC.
18.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
18.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
18.6.5.1
COMPANY FOOTPRINT
18.6.5.2
OFFERING FOOTPRINT
18.6.5.3
TECHNOLOGY FOOTPRINT
18.6.5.4
APPLICATION FOOTPRINT
18.7
COMPANY EVALUATION MATRIX: START-UPS/SMES,
18.7.1
PROGRESSIVE COMPANIES
18.7.2
RESPONSIVE COMPANIES
18.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
18.7.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
18.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
18.8
COMPANY VALUATION & FINANCIAL METRICS
18.9
COMPETITIVE SCENARIO
18.9.1
PRODUCT/SERVICE LAUNCHES
19.1.2
THERMO FISHER SCIENTIFIC INC.
19.1.3
AGILENT TECHNOLOGIES, INC.
19.1.4
F. HOFFMANN-LA ROCHE LTD.
19.1.6
OXFORD NANOPORE TECHNOLOGIES
19.1.8
EUROFINS SCIENTIFIC
20.1.1.1
KEY DATA FROM SECONDARY SOURCES
20.1.2.1
KEY DATA FROM PRIMARY SOURCES
20.1.2.2
KEY PRIMARY PARTICIPANTS
20.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
20.1.2.4
KEY INDUSTRY INSIGHTS
20.2
MARKET SIZE ESTIMATION
20.2.1
FRANCE NEXT-GENERATION SEQUENCING MARKET ESTIMATION,
20.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
20.2.1.2
MNM REPOSITORY ANALYSIS
20.2.1.3
PRIMARY RESEARCH
20.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
20.3
MARKET GROWTH RATE PROJECTIONS
20.6
RESEARCH ASSUMPTIONS
20.7
RESEARCH LIMITATIONS & RISK ASSESSMENT
21.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in France Next Generation Sequencing Market